The EZH2 inhibitor tazemetostat has been approved by the the United States Food and Drug Administration (US FDA) for treating certain lymphomas [96], demonstrating a 69% objective response rate in EZH2‐mutant patients during a phase II clinical trial [97]. This evidence concerns the gene EZH2 and lymphoma.